Go Pro
→ Gold buyout deals have handed shareholders overnight gains up to 79 percent (From Golden Portfolio) (Ad)tc pixel Free ALNY Stock Alerts

Alnylam Pharmaceuticals (ALNY) Financials

Alnylam Pharmaceuticals logo
$228.65 +1.53 (+0.67%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$226.25 -2.40 (-1.05%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Alnylam Pharmaceuticals

Annual Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278 314
Consolidated Net Income / (Loss)		 -290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278 314
Net Income / (Loss) Continuing Operations		 -290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278 314
Total Pre-Tax Income 		-290 -410 -491 -761 -885 -856 -852 -1,127 -434 -377 323
Total Operating Income		 -296 -425 -500 -815 -939 -828 -709 -785 -282 -177 502
Total Gross Profit		 41 47 90 73 195 415 704 869 1,518 1,925 3,032
Total Revenue		 41 47 90 75 220 493 844 1,037 1,828 2,248 3,714
Operating Revenue		 41 47 90 75 220 493 844 1,037 1,828 2,248 3,714
Total Cost of Revenue		 0.00 0.00 0.00 1.80 25 78 140 169 310 323 682
Operating Cost of Revenue		 - - 0.00 1.80 25 78 140 169 310 323 682
Total Operating Expenses		 337 472 590 888 1,134 1,243 1,413 1,654 1,800 2,102 2,530
Selling, General & Admin Expense		 61 89 199 382 479 588 621 771 796 976 1,211
Research & Development Expense		 276 382 391 505 655 655 792 883 1,004 1,126 1,320
Total Other Income / (Expense), net		 5.94 14 9.21 54 54 -27 -143 -342 -151 -200 -178
Interest Expense		 - - - 0.00 0.00 84 143 233 121 142 295
Interest & Investment Income		 5.86 8.31 12 29 33 - 1.58 25 96 122 111
Other Income / (Expense), net		 0.08 6.17 -3.02 25 21 57 -2.05 -134 -126 -181 5.20
Income Tax Expense		 - 0.00 0.00 0.82 0.86 2.68 0.68 4.16 6.73 -99 9.41
Basic Earnings per Share		 ($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18) $2.39
Weighted Average Basic Shares Outstanding		 83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 118.45M 121.69M 124.91M 127.65M 131.00M
Diluted Earnings per Share		 ($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18) $2.33
Weighted Average Diluted Shares Outstanding		 83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 118.45M 121.69M 124.91M 127.65M 134.68M
Weighted Average Basic & Diluted Shares Outstanding		 83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 120.21M 124.13M 125.95M 129.46M 132.62M

Quarterly Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -138 -66 -17 -112 -84 -18 -72 251 186 206 164
Consolidated Net Income / (Loss)		 -138 -66 -17 -112 -84 -18 -72 251 186 206 164
Net Income / (Loss) Continuing Operations		 -138 -66 -17 -112 -84 -18 -72 251 186 206 164
Total Pre-Tax Income 		-138 -64 -11 -109 -194 -2.37 -41 239 161 222 178
Total Operating Income		 -116 -43 49 -77 -105 18 -16 368 132 269 231
Total Gross Profit		 354 428 591 415 490 523 631 1,049 829 956 992
Total Revenue		 440 494 660 501 593 594 774 1,249 1,097 1,167 1,291
Operating Revenue		 440 494 660 501 593 594 774 1,249 1,097 1,167 1,291
Total Cost of Revenue		 86 66 69 86 103 71 143 200 268 211 298
Operating Cost of Revenue		 86 66 69 86 103 71 143 200 268 211 298
Total Operating Expenses		 470 472 543 492 596 505 647 681 698 687 761
Selling, General & Admin Expense		 198 211 248 221 295 240 323 322 325 323 348
Research & Development Expense		 272 261 294 271 300 265 324 359 372 365 413
Total Other Income / (Expense), net		 -21 -20 -60 -32 -89 -20 -25 -129 29 -47 -54
Interest Expense		 31 35 33 34 39 58 61 84 133 69 82
Interest & Investment Income		 30 30 29 32 31 29 27 29 27 27 28
Other Income / (Expense), net		 -20 -15 -56 -30 -81 9.19 8.86 -74 135 -4.30 0.27
Income Tax Expense		 0.18 2.35 5.72 2.91 -110 16 31 -12 -25 16 13
Basic Earnings per Share		 ($1.09) ($0.52) ($0.13) ($0.87) ($0.66) ($0.14) ($0.55) $1.91 $1.43 $1.55 $1.23
Weighted Average Basic Shares Outstanding		 124.91M 126.14M 126.73M 128.59M 127.65M 129.68M 130.63M 131.45M 131.00M 132.89M 133.61M
Diluted Earnings per Share		 ($1.06) ($0.52) ($0.13) ($0.87) ($0.66) ($0.14) ($0.55) $1.84 $1.44 $1.51 $1.21
Weighted Average Diluted Shares Outstanding		 124.91M 126.14M 126.73M 128.59M 127.65M 129.68M 130.63M 137.35M 134.68M 138.23M 138.28M
Weighted Average Basic & Diluted Shares Outstanding		 125.95M 126.49M 128.38M 128.98M 129.46M 130.39M 131.08M 132.11M 132.62M 133.51M 133.81M

Annual Cash Flow Statements for Alnylam Pharmaceuticals

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 106 13 452 -224 127 -51 323 46 -54 154 690
Net Cash From Operating Activities		 -189 -308 -383 -563 -278 -615 -642 -541 104 -8.31 524
Net Cash From Continuing Operating Activities		 -189 -308 -383 -563 -278 -615 -642 -541 104 -8.31 524
Net Income / (Loss) Continuing Operations		 -290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278 314
Consolidated Net Income / (Loss)		 -290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278 314
Depreciation Expense		 19 15 12 15 17 35 48 44 54 57 56
Non-Cash Adjustments To Reconcile Net Income		 47 72 95 170 164 170 227 445 345 402 631
Changes in Operating Assets and Liabilities, net		 35 15 1.48 14 390 -1.44 -105 101 145 -189 -477
Net Cash From Investing Activities		 -321 143 -290 273 -418 -436 -273 169 -336 -117 436
Net Cash From Continuing Investing Activities		 -321 143 -290 273 -418 -436 -273 169 -336 -117 436
Purchase of Property, Plant & Equipment		 -13 -65 -104 -127 -140 -70 -76 -72 -62 -34 -59
Purchase of Investments		 -1,035 -909 -903 -1,119 -2,076 -2,052 -1,698 -2,075 -1,882 -1,712 -1,365
Sale and/or Maturity of Investments		 727 1,116 717 1,519 1,805 1,692 1,506 2,322 1,612 1,630 1,862
Other Investing Activities, net		 - - 0.00 0.00 -7.00 -5.30 -4.20 -4.69 -4.44 -0.12 -2.15
Net Cash From Financing Activities		 616 178 1,125 65 823 995 1,247 426 172 294 -305
Net Cash From Continuing Financing Activities		 616 178 1,125 65 823 995 1,247 426 172 294 -305
Repayment of Debt		 - - -120 0.00 - 0.00 500 -762 0.00 0.00 -1,157
Issuance of Debt		 - 150 - 0.00 0.00 200 0.00 1,016 0.00 0.00 646
Issuance of Common Equity		 617 28 1,245 65 853 300 246 259 147 303 250
Other Financing Activities, net		 0.38 -0.60 - 0.00 -30 495 501 -88 25 -8.79 -44
Effect of Exchange Rate Changes		 - - - - -0.08 4.92 -9.02 -7.43 6.39 -15 35
Cash Interest Paid		 - 1.10 2.43 - 0.17 0.00 25 45 32 68 219

Quarterly Cash Flow Statements for Alnylam Pharmaceuticals

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -220 -130 286 131 -134 54 94 377 166 54 -2.94
Net Cash From Operating Activities		 -30 -82 124 44 -95 -120 154 325 164 71 327
Net Cash From Continuing Operating Activities		 -30 -82 124 44 -95 -120 154 325 164 71 327
Net Income / (Loss) Continuing Operations		 -138 -66 -17 -112 -84 -18 -66 251 186 206 164
Consolidated Net Income / (Loss)		 -138 -66 -17 -112 -84 -18 -66 251 186 206 164
Depreciation Expense		 13 14 15 14 14 14 14 14 14 14 14
Non-Cash Adjustments To Reconcile Net Income		 69 77 120 78 127 112 150 188 201 136 166
Changes in Operating Assets and Liabilities, net		 58 -106 -3.84 50 -117 -229 57 -128 -237 -285 -17
Net Cash From Investing Activities		 -241 -68 34 -30 -53 114 -141 501 -37 -26 -363
Net Cash From Continuing Investing Activities		 -241 -68 34 -30 -53 114 -141 501 -37 -26 -363
Purchase of Property, Plant & Equipment		 -15 -13 -8.02 -4.19 -9.09 -8.97 -14 -12 -23 -22 -35
Purchase of Investments		 -589 -460 -316 -450 -487 -450 -469 -210 -236 -266 -594
Sale and/or Maturity of Investments		 364 405 358 424 443 573 342 725 222 262 291
Net Cash From Financing Activities		 39 29 131 103 31 46 54 -448 45 16 36
Net Cash From Continuing Financing Activities		 39 29 131 103 31 46 54 -448 45 16 36
Repayment of Debt		 - - - - - 0.00 - - -52 -0.01 -0.01
Issuance of Common Equity		 31 26 133 108 36 49 81 78 42 13 34
Other Financing Activities, net		 8.33 3.05 -1.28 -5.28 -5.28 -3.28 -27 -67 57 2.57 2.68
Effect of Exchange Rate Changes		 11 -9.94 -3.12 15 -17 14 28 -0.93 -5.70 -7.06 -2.45
Cash Interest Paid		 5.44 31 8.16 16 12 69 15 24 113 64 58
Cash Income Taxes Paid		 - 1.99 - - - 2.97 -1.87 1.28 - 2.37 12

Annual Balance Sheets for Alnylam Pharmaceuticals

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1,387 1,263 1,995 1,575 2,395 3,407 3,643 3,546 3,830 4,240 4,966
Total Current Assets		 1,105 672 1,765 1,201 1,716 2,615 2,809 2,692 2,983 3,295 4,051
Cash & Equivalents		 181 194 645 420 547 497 820 866 813 966 1,657
Short-Term Investments		 900 433 1,045 664 989 1,378 1,616 1,326 1,627 1,728 1,251
Accounts Receivable		 8.30 23 34 19 43 102 199 238 328 405 778
Inventories, net		 - - - 24 56 75 86 129 89 79 83
Prepaid Expenses		 17 22 40 74 80 63 88 133 126 117 282
Plant, Property, & Equipment, net		 28 115 182 321 425 465 502 523 526 503 513
Total Noncurrent Assets		 253 476 48 53 254 327 333 331 321 442 403
Long-Term Investments		 252 475 44 45 15 41 41 49 49 69 22
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 10 117 126
Other Noncurrent Operating Assets		 1.47 1.56 4.17 8.62 239 287 292 281 262 256 254
Total Liabilities & Shareholders' Equity		 1,387 1,263 1,995 1,575 2,395 3,407 3,643 3,546 3,830 4,240 4,966
Total Liabilities		 122 343 228 273 956 2,391 3,055 3,705 4,051 4,173 4,177
Total Current Liabilities		 62 132 144 179 353 585 696 768 968 1,186 1,466
Accounts Payable		 17 54 28 60 50 52 73 98 56 88 116
Accrued Expenses		 29 42 72 113 197 356 395 545 713 794 1,080
Current Deferred Revenue		 17 35 44 7.07 78 127 149 42 103 55 4.85
Other Current Liabilities		 - - - 0.00 28 50 78 82 97 249 266
Total Noncurrent Liabilities		 60 211 84 93 604 1,614 2,359 2,937 3,083 2,987 2,711
Long-Term Debt		 - 150 30 30 0.00 - 676 1,017 1,021 1,025 1,008
Other Noncurrent Operating Liabilities		 1.30 3.07 4.35 4.97 285 1,389 1,531 1,726 1,874 1,962 1,703
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,265 920 1,766 1,302 1,439 1,016 588 -158 -221 67 789
Total Preferred & Common Equity		 1,265 920 1,766 1,302 1,439 1,016 588 -158 -221 67 789
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,265 920 1,766 1,302 1,439 1,016 588 -158 -221 67 789
Common Stock		 2,507 2,610 3,949 4,176 5,202 5,645 6,060 6,456 6,812 7,389 7,512
Retained Earnings		 -1,247 -1,657 -2,148 -2,841 -3,727 -4,585 -5,438 -6,569 -7,010 -7,288 -6,703
Accumulated Other Comprehensive Income / (Loss)		 4.37 -33 -34 -33 -37 -44 -33 -45 -23 -35 -20

Quarterly Balance Sheets for Alnylam Pharmaceuticals

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 3,392 3,402 3,839 3,824 4,010 4,205 4,214 4,566 4,852 5,130 5,559
Total Current Assets		 2,541 2,524 2,985 2,989 3,173 3,355 3,268 3,644 3,953 4,219 4,620
Cash & Equivalents		 672 658 1,033 682 968 1,100 1,020 1,114 1,490 1,711 1,708
Short-Term Investments		 1,398 1,400 1,373 1,689 1,656 1,680 1,613 1,744 1,234 1,298 1,600
Accounts Receivable		 219 221 325 321 309 354 418 567 965 884 913
Inventories, net		 132 100 96 94 84 76 66 72 75 84 97
Prepaid Expenses		 119 145 158 202 155 145 152 147 188 242 302
Plant, Property, & Equipment, net		 523 527 526 523 517 507 499 500 502 518 554
Total Noncurrent Assets		 328 351 328 312 320 343 447 423 397 392 384
Long-Term Investments		 49 49 49 49 49 69 69 69 51 22 22
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - 107 104 99 117 114
Other Noncurrent Operating Assets		 279 301 279 263 270 274 271 250 247 253 248
Total Liabilities & Shareholders' Equity		 3,392 3,402 3,839 3,824 4,010 4,205 4,214 4,566 4,852 5,130 5,559
Total Liabilities		 3,651 3,811 4,005 4,044 4,013 4,173 4,098 4,315 4,618 4,054 4,205
Total Current Liabilities		 673 789 950 942 1,055 1,221 1,076 1,301 1,555 1,349 1,513
Accounts Payable		 62 60 74 78 74 71 97 102 118 127 108
Accrued Expenses		 509 599 713 699 809 946 704 919 1,154 946 1,096
Current Deferred Revenue		 36 55 77 77 69 71 28 15 2.54 3.21 4.01
Other Current Liabilities		 67 76 86 88 104 133 246 264 282 273 305
Total Noncurrent Liabilities		 2,978 3,022 3,055 3,102 2,957 2,952 3,023 3,015 3,062 2,705 2,692
Long-Term Debt		 1,018 1,019 1,020 1,022 1,023 1,024 1,026 1,027 1,040 1,009 1,011
Other Noncurrent Operating Liabilities		 1,769 1,809 1,839 1,895 1,932 1,927 1,997 1,988 2,022 1,695 1,681
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -259 -408 -166 -219 -3.07 32 115 251 234 1,075 1,354
Total Preferred & Common Equity		 -259 -408 -166 -219 -3.07 32 115 251 234 1,075 1,354
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -259 -408 -166 -219 -3.07 32 115 251 234 1,075 1,354
Common Stock		 6,523 6,648 6,738 6,883 7,124 7,261 7,498 7,692 7,416 7,597 7,718
Retained Earnings		 -6,743 -7,019 -6,872 -7,076 -7,092 -7,204 -7,345 -7,412 -7,160 -6,497 -6,332
Accumulated Other Comprehensive Income / (Loss)		 -39 -37 -32 -27 -35 -25 -38 -30 -22 -25 -32

Annual Metrics And Ratios for Alnylam Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -18.72% 14.75% 90.66% -16.69% 193.36% 124.28% 71.31% 22.88% 76.23% 22.97% 65.19%
EBITDA Growth		 29.23% -45.65% -21.80% -57.71% -11.57% 19.40% 10.86% -40.86% 59.56% 14.97% 286.96%
EBIT Growth		 26.60% -41.39% -20.24% -57.01% -16.30% 16.07% 7.83% -29.34% 55.63% 12.34% 241.75%
NOPAT Growth		 26.91% -43.44% -17.78% -62.91% -15.31% 11.81% 14.46% -10.78% 64.06% 37.31% 493.30%
Net Income Growth		 19.51% -41.38% -19.69% -55.13% -16.37% 3.14% 0.64% -32.64% 61.08% 36.82% 212.79%
EPS Growth		 28.87% -38.84% -13.15% -39.67% -7.13% 8.01% 3.49% -29.17% 62.15% 38.07% 206.88%
Operating Cash Flow Growth		 -14.19% -62.68% -24.40% -46.98% 50.51% -120.87% -4.35% 15.65% 119.24% -107.98% 6,405.10%
Free Cash Flow Firm Growth		 51.25% -85.48% -32.94% -60.46% 51.88% 104.50% -42.16% -4,357.02% 128.50% -230.57% 64.05%
Invested Capital Growth		 -68.11% 53.62% 297.26% 227.96% -155.32% -530.12% -71.36% -14.06% -22.09% 1.02% 32.17%
Revenue Q/Q Growth		 -28.61% 26.58% 29.48% -18.40% 29.95% 22.91% 12.67% 7.96% 6.07% 7.33% 15.70%
EBITDA Q/Q Growth		 -19.40% -4.89% -6.99% -9.62% -7.04% 10.94% -3.27% -0.48% 2.89% -45.28% 411.66%
EBIT Q/Q Growth		 -18.75% -4.17% -6.64% -10.52% -7.26% 9.34% -2.93% 3.51% 11.77% -15.98% 845.40%
NOPAT Q/Q Growth		 -18.78% -5.71% -6.81% -9.85% -9.02% 11.14% -0.05% 0.75% 20.38% 5.98% 162.82%
Net Income Q/Q Growth		 -31.41% -5.73% -6.35% -10.00% -7.88% 3.66% -1.78% 4.31% 13.66% 16.28% 620.18%
EPS Q/Q Growth		 -45.57% -5.51% -3.24% -8.76% -4.38% 4.36% -0.84% 4.81% 15.18% 15.50% 913.04%
Operating Cash Flow Q/Q Growth		 -9.51% -8.95% -6.90% -9.20% -19.55% 10.59% -4.39% 3.25% 5,179.07% -114.70% 97.12%
Free Cash Flow Firm Q/Q Growth		 -3.81% -12.41% -4.44% -3.61% -38.06% 111.17% -77.55% -3.45% 949.02% -337.48% 52.05%
Invested Capital Q/Q Growth		 -27.09% 16.85% 4.91% -10.37% 12.81% -9.95% -2.84% -1.22% -5.43% 6.77% 24.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 97.59% 88.60% 84.16% 83.40% 83.73% 83.02% 85.62% 81.64%
EBITDA Margin		 -673.73% -855.16% -546.33% -1,034.19% -393.33% -141.35% -73.55% -84.32% -19.35% -13.38% 15.14%
Operating Margin		 -720.27% -900.33% -556.20% -1,087.56% -427.50% -168.09% -83.94% -75.68% -15.43% -7.87% 13.51%
EBIT Margin		 -720.08% -887.25% -559.56% -1,054.54% -418.07% -156.46% -84.18% -88.61% -22.31% -15.90% 13.65%
Profit (Net Income) Margin		 -705.83% -869.63% -545.95% -1,016.58% -403.24% -174.15% -101.01% -109.04% -24.08% -12.37% 8.45%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.11% 100.10% 100.31% 100.08% 100.37% 101.55% 73.71% 97.09%
Interest Burden Percent		 98.02% 98.01% 97.57% 96.30% 96.36% 110.96% 119.90% 122.60% 106.29% 105.56% 63.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91%
Return on Invested Capital (ROIC)		 0.00% 0.00% -2,294.21% -430.59% -1,450.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -2,283.60% -416.95% -1,432.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 2,257.67% 380.96% 1,385.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -26.36% -37.54% -36.54% -49.63% -64.66% -69.92% -106.31% -526.14% 232.40% 362.29% 73.28%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -716.28% -537.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -24.00% -31.59% -30.89% -44.26% -46.28% -26.58% -20.16% -25.57% -11.06% -8.86% 11.01%
Return on Assets (ROA)		 -23.52% -30.96% -30.14% -42.67% -44.64% -29.58% -24.19% -31.47% -11.94% -6.89% 6.82%
Return on Common Equity (ROCE)		 -26.36% -37.54% -36.54% -49.63% -64.66% -69.92% -106.31% -526.14% 232.40% 362.29% 73.28%
Return on Equity Simple (ROE_SIMPLE)		 -22.94% -44.57% -27.79% -58.49% -61.59% -84.46% -144.99% 714.91% 199.53% -414.62% 0.00%
Net Operating Profit after Tax (NOPAT)		 -207 -297 -350 -570 -658 -580 -496 -550 -198 -124 487
NOPAT Margin		 -504.19% -630.23% -389.34% -761.30% -299.25% -117.66% -58.75% -52.97% -10.80% -5.51% 13.11%
Net Nonoperating Expense Percent (NNEP)		 -7.18% -9.89% -10.60% -13.64% -17.25% -17.00% -20.24% -38.45% -18.03% -9.63% -9.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -64.00% -24.69% -11.34% 27.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 2.41% 11.40% 15.84% 16.60% 16.27% 16.98% 14.38% 18.36%
SG&A Expenses to Revenue		 147.48% 189.47% 221.73% 510.44% 217.98% 119.39% 73.51% 74.29% 43.52% 43.39% 32.60%
R&D to Revenue		 672.79% 810.86% 434.46% 674.72% 298.12% 132.86% 93.83% 85.12% 54.94% 50.09% 35.54%
Operating Expenses to Revenue		 820.27% 1,000.33% 656.20% 1,185.16% 516.10% 252.25% 167.34% 159.40% 98.46% 93.48% 68.13%
Earnings before Interest and Taxes (EBIT)		 -296 -418 -503 -790 -919 -771 -711 -919 -408 -358 507
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -277 -403 -491 -775 -864 -697 -621 -875 -354 -301 562
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.31 3.49 6.67 5.66 8.93 14.86 34.48 0.00 0.00 452.40 66.57
Price to Tangible Book Value (P/TBV)		 6.31 3.49 6.67 5.66 8.93 14.86 34.48 0.00 0.00 452.40 66.57
Price to Revenue (P/Rev)		 194.10 68.13 131.03 98.34 58.43 30.64 24.02 28.18 13.14 13.50 14.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 167.44
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.60%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 162.81 30.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 161.68 47.95 112.08 83.66 51.37 26.75 21.89 27.00 12.34 12.73 13.63
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 89.99
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 99.87
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 103.93
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 216.53 0.00 96.57
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 856.53 2,075.70 0.00 208.74 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.16 0.02 0.02 0.00 0.00 1.15 -6.43 -4.63 15.27 1.28
Long-Term Debt to Equity		 0.00 0.16 0.02 0.02 0.00 0.00 1.15 -6.43 -4.63 15.27 1.28
Financial Leverage		 -1.05 -1.05 -0.99 -0.91 -0.97 -1.33 -2.20 -7.04 7.11 20.88 -4.28
Leverage Ratio		 1.12 1.21 1.21 1.16 1.45 2.36 4.39 16.72 -19.47 -52.55 10.75
Compound Leverage Factor		 1.10 1.19 1.18 1.12 1.40 2.62 5.27 20.50 -20.69 -55.47 6.86
Debt to Total Capital		 0.00% 14.02% 1.67% 2.25% 0.00% 0.00% 53.46% 118.43% 127.58% 93.85% 56.08%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 14.02% 1.67% 2.25% 0.00% 0.00% 53.46% 118.43% 127.58% 93.85% 56.08%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 85.98% 98.33% 97.75% 100.00% 100.00% 46.54% -18.43% -27.58% 6.15% 43.92%
Debt to EBITDA		 0.00 -0.37 -0.06 -0.04 0.00 0.00 -1.09 -1.16 -2.89 -3.41 1.79
Net Debt to EBITDA		 0.00 2.36 3.47 1.42 0.00 0.00 2.90 1.40 4.15 5.78 -3.42
Long-Term Debt to EBITDA		 0.00 -0.37 -0.06 -0.04 0.00 0.00 -1.09 -1.16 -2.89 -3.41 1.79
Debt to NOPAT		 0.00 -0.50 -0.09 -0.05 0.00 0.00 -1.36 -1.85 -5.17 -8.28 2.07
Net Debt to NOPAT		 0.00 3.20 4.87 1.93 0.00 0.00 3.63 2.23 7.43 14.04 -3.95
Long-Term Debt to NOPAT		 0.00 -0.50 -0.09 -0.05 0.00 0.00 -1.36 -1.85 -5.17 -8.28 2.07
Altman Z-Score		 38.27 3.25 29.64 12.84 5.39 2.02 2.18 2.23 1.75 2.81 7.37
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 17.80 5.10 12.23 6.69 4.87 4.47 4.04 3.51 3.08 2.78 2.76
Quick Ratio		 17.53 4.94 11.96 6.14 4.48 3.38 3.79 3.16 2.86 2.61 2.51
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -180 -333 -443 -711 -342 15 8.90 -379 108 -141 -51
Operating Cash Flow to CapEx		 -1,460.54% -476.63% -367.33% -443.40% -198.66% -874.01% -840.22% -751.15% 167.42% -24.25% 892.86%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.18 0.06 -1.63 0.89 -0.99 -0.17
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -7.28 -4.49 -2.33 0.86 -0.06 1.78
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -8.11 -5.02 -2.64 0.35 -0.30 1.58
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.04 0.06 0.04 0.11 0.17 0.24 0.29 0.50 0.56 0.81
Accounts Receivable Turnover		 1.70 2.98 3.14 2.84 7.12 6.78 5.61 4.75 6.46 6.13 6.28
Inventory Turnover		 0.00 0.00 0.00 0.00 0.62 1.19 1.73 1.57 2.85 3.86 8.46
Fixed Asset Turnover		 1.66 0.66 0.61 0.30 0.59 1.11 1.75 2.02 3.48 4.37 7.31
Accounts Payable Turnover		 0.00 0.00 0.00 0.04 0.46 1.53 2.24 1.97 4.04 4.49 6.68
Days Sales Outstanding (DSO)		 214.20 122.41 116.38 128.55 51.30 53.85 65.06 76.79 56.47 59.51 58.13
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 585.58 307.59 210.40 232.78 128.23 94.62 43.15
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 8,918.70 798.04 238.14 163.29 185.42 90.32 81.23 54.64
Cash Conversion Cycle (CCC)		 214.20 122.41 116.38 -8,790.15 -161.16 123.29 112.17 124.15 94.39 72.90 46.64
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -68 -31 62 203 -112 -708 -1,213 -1,383 -1,689 -1,671 -1,134
Invested Capital Turnover		 -0.76 -0.95 5.89 0.57 4.85 -1.20 -0.88 -0.80 -1.19 -1.34 -2.65
Increase / (Decrease) in Invested Capital		 -27 36 93 141 -315 -595 -505 -171 -306 17 538
Enterprise Value (EV)		 6,645 2,261 10,077 6,267 11,289 13,185 18,481 28,013 22,553 28,612 50,612
Market Capitalization		 7,977 3,213 11,781 7,366 12,840 15,100 20,282 29,238 24,021 30,350 52,535
Book Value per Share		 $14.93 $10.72 $19.05 $12.89 $12.90 $8.75 $4.92 ($1.29) ($1.76) $0.52 $5.97
Tangible Book Value per Share		 $14.93 $10.72 $19.05 $12.89 $12.90 $8.75 $4.92 ($1.29) ($1.76) $0.52 $5.97
Total Capital		 1,265 1,070 1,796 1,332 1,439 1,016 1,264 859 800 1,092 1,797
Total Debt		 0.00 150 30 30 0.00 0.00 676 1,017 1,021 1,025 1,008
Total Long-Term Debt		 0.00 150 30 30 0.00 0.00 676 1,017 1,021 1,025 1,008
Net Debt		 -1,332 -952 -1,705 -1,099 -1,551 -1,915 -1,801 -1,225 -1,468 -1,738 -1,923
Capital Expenditures (CapEx)		 13 65 104 127 140 70 76 72 62 34 59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -37 -87 -70 -63 -173 155 -323 -268 -424 -585 -324
Debt-free Net Working Capital (DFNWC)		 1,043 540 1,620 1,021 1,363 2,030 2,113 1,924 2,015 2,109 2,584
Net Working Capital (NWC)		 1,043 540 1,620 1,021 1,363 2,030 2,113 1,924 2,015 2,109 2,584
Net Nonoperating Expense (NNE)		 83 113 141 191 229 278 357 582 243 154 173
Net Nonoperating Obligations (NNO)		 -1,332 -952 -1,705 -1,099 -1,551 -1,724 -1,801 -1,225 -1,468 -1,738 -1,923
Total Depreciation and Amortization (D&A)		 19 15 12 15 54 74 90 44 54 57 56
Debt-free, Cash-free Net Working Capital to Revenue		 -90.62% -183.68% -78.00% -84.04% -78.68% 31.47% -38.22% -25.84% -23.22% -26.04% -8.73%
Debt-free Net Working Capital to Revenue		 2,538.60% 1,145.44% 1,802.31% 1,363.28% 620.37% 411.79% 250.25% 185.49% 110.21% 93.81% 69.58%
Net Working Capital to Revenue		 2,538.60% 1,145.44% 1,802.31% 1,363.28% 620.37% 411.79% 250.25% 185.49% 110.21% 93.81% 69.58%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18) $2.39
Adjusted Weighted Average Basic Shares Outstanding		 85.14M 86.01M 99.87M 106.26M 112.58M 117.00M 118.45M 121.69M 124.91M 127.65M 131.00M
Adjusted Diluted Earnings per Share		 ($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18) $2.33
Adjusted Weighted Average Diluted Shares Outstanding		 85.14M 86.01M 99.87M 106.26M 112.58M 117.00M 118.45M 121.69M 124.91M 127.65M 134.68M
Adjusted Basic & Diluted Earnings per Share		 ($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 120.21M 124.13M 125.95M 129.46M 132.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -207 -297 -350 -570 -658 -580 -496 -550 -198 -124 487
Normalized NOPAT Margin		 -504.19% -630.23% -389.34% -761.30% -299.25% -117.66% -58.75% -52.97% -10.80% -5.51% 13.11%
Pre Tax Income Margin		 -705.83% -869.63% -545.95% -1,015.48% -402.85% -173.60% -100.93% -108.63% -23.71% -16.79% 8.70%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -9.13 -4.97 -3.95 -3.36 -2.52 1.72
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -6.86 -3.47 -2.36 -1.63 -0.87 1.65
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -9.96 -5.50 -4.26 -3.88 -2.76 1.52
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -7.70 -4.00 -2.67 -2.14 -1.11 1.45
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Alnylam Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 132,623,144.00 133,512,573.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 132,623,144.00 133,512,573.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 1.55 1.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 31.25% 54.82% 107.00% -33.26% 34.90% 20.20% 17.26% 149.35% 84.95% 96.43% 66.86%
EBITDA Growth		 30.30% 76.11% 107.28% -144.17% -39.40% 61.27% -209.38% 432.75% 263.34% 566.84% 3,618.59%
EBIT Growth		 28.47% 64.22% 97.33% -168.14% -36.01% 45.46% -218.69% 376.07% 243.64% 869.42% 3,257.30%
NOPAT Growth		 38.28% 71.01% 121.15% -125.68% 9.66% 141.62% -133.32% 818.21% 307.01% 1,872.94% 1,988.24%
Net Income Growth		 33.55% 62.13% 93.88% -175.51% 39.24% 12.82% -292.43% 325.05% 322.56% 1,228.66% 327.74%
EPS Growth		 37.28% 62.86% 94.12% -175.65% 37.74% 15.38% -292.31% 311.49% 318.18% 1,178.57% 320.00%
Operating Cash Flow Growth		 77.42% 51.03% 310.49% -87.84% -217.71% -45.14% 23.82% 643.84% 272.78% 158.60% 151.70%
Free Cash Flow Firm Growth		 482.15% 319.44% 561.59% -69.15% -140.55% -120.21% -108.68% -30.36% -324.05% -694.66% -2,713.90%
Invested Capital Growth		 -22.09% -18.86% -10.58% -11.93% 1.02% 3.61% 0.32% 16.23% 32.17% 39.31% 41.47%
Revenue Q/Q Growth		 -41.41% 12.42% 33.48% -24.08% 18.42% 0.17% 30.21% 61.44% -12.17% 6.39% 10.60%
EBITDA Q/Q Growth		 -168.58% 71.19% 154.17% -551.08% -116.43% 89.98% 49.74% 3,654.83% -8.76% -0.99% -11.62%
EBIT Q/Q Growth		 -187.55% 57.60% 87.77% -1,400.96% -74.76% 83.00% 28.54% 1,400.26% -9.07% -1.06% -12.34%
NOPAT Q/Q Growth		 -138.87% 62.69% 211.92% -258.20% -36.74% 117.19% -189.61% 3,509.71% -60.59% 63.83% -14.24%
Net Income Q/Q Growth		 -193.31% 52.18% 74.39% -560.61% 24.92% 31.38% -15.31% 478.84% -25.75% 10.50% -20.15%
EPS Q/Q Growth		 -192.17% 50.94% 75.00% -569.23% 24.14% 33.33% -15.91% 460.78% -21.74% 4.86% -19.87%
Operating Cash Flow Q/Q Growth		 -108.29% -173.59% 252.31% -64.80% -316.58% -24.99% 229.93% 111.48% -49.69% -56.89% 363.41%
Free Cash Flow Firm Q/Q Growth		 -49.64% 1.03% -15.07% -28.61% -166.20% 49.66% 63.51% 672.60% -503.10% 5.66% -29.22%
Invested Capital Q/Q Growth		 -5.43% 4.17% -2.24% -8.37% 6.77% 6.68% -5.72% 8.93% 24.51% 16.50% -1.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 80.47% 86.65% 89.59% 82.85% 82.67% 88.04% 81.52% 83.98% 75.60% 81.91% 76.88%
EBITDA Margin		 -28.03% -6.57% 2.67% -15.85% -28.97% -2.90% -1.12% 24.63% 25.59% 23.81% 19.03%
Operating Margin		 -26.47% -8.79% 7.37% -15.35% -17.73% 3.04% -2.09% 29.46% 12.01% 23.02% 17.93%
EBIT Margin		 -31.10% -11.73% -1.07% -21.25% -31.36% -5.32% -2.92% 23.52% 24.35% 22.65% 17.95%
Profit (Net Income) Margin		 -31.35% -13.34% -2.56% -22.27% -14.12% -9.67% -8.57% 20.10% 16.99% 17.65% 12.74%
Tax Burden Percent		 100.13% 103.69% 151.24% 102.68% 43.19% 138.18% 187.45% 105.07% 115.69% 92.93% 92.51%
Interest Burden Percent		 100.68% 109.67% 157.48% 102.10% 104.28% 131.54% 156.47% 81.33% 60.31% 83.85% 76.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.07% -15.69% 7.07% 7.49%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 232.40% 138.80% 35.48% 497.73% 362.29% 519.47% -257.82% 32.73% 73.28% 90.36% 96.55%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -15.42% -6.51% -0.68% -11.07% -17.47% -3.11% -1.68% 16.68% 19.65% 20.78% 17.03%
Return on Assets (ROA)		 -15.54% -7.41% -1.62% -11.60% -7.87% -5.65% -4.92% 14.25% 13.71% 16.20% 12.09%
Return on Common Equity (ROCE)		 232.40% 138.80% 35.48% 497.73% 362.29% 519.47% -257.82% 32.73% 73.28% 90.36% 96.55%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 151.44% 2,378.25% -1,026.96% 0.00% -233.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -81 -30 34 -54 -74 13 -11 387 152 250 214
NOPAT Margin		 -18.53% -6.15% 5.16% -10.75% -12.41% 2.13% -1.47% 30.96% 13.89% 21.39% 16.59%
Net Nonoperating Expense Percent (NNEP)		 -4.19% -2.84% -3.72% -3.54% -0.63% -4.56% -3.09% -7.61% 1.86% -2.36% -2.35%
Return On Investment Capital (ROIC_SIMPLE)		 -10.18% - - - -6.74% 1.11% -0.89% 30.34% 8.48% 11.98% 9.05%
Cost of Revenue to Revenue		 19.53% 13.35% 10.41% 17.15% 17.33% 11.96% 18.48% 16.02% 24.40% 18.09% 23.12%
SG&A Expenses to Revenue		 45.06% 42.64% 37.65% 44.12% 49.79% 40.38% 41.79% 25.79% 29.66% 27.64% 26.95%
R&D to Revenue		 61.89% 52.80% 44.58% 54.09% 50.60% 44.62% 41.83% 28.73% 33.93% 31.26% 32.00%
Operating Expenses to Revenue		 106.95% 95.44% 82.22% 98.20% 100.39% 85.00% 83.62% 54.51% 63.59% 58.90% 58.95%
Earnings before Interest and Taxes (EBIT)		 -137 -58 -7.09 -106 -186 -32 -23 294 267 264 232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -123 -32 18 -79 -172 -17 -8.65 308 281 278 246
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1,091.32 452.40 302.82 169.67 255.55 66.57 40.81 29.68
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 1,091.32 452.40 302.82 169.67 255.55 66.57 40.81 29.68
Price to Revenue (P/Rev)		 13.14 9.36 13.11 16.86 13.50 14.89 17.27 18.62 14.15 10.24 8.37
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,372.02 167.44 81.56 51.88
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.07% 0.60% 1.23% 1.93%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 12.34 8.66 12.41 15.98 12.73 14.17 16.50 18.08 13.63 9.76 7.88
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 558.63 0.00 0.00 0.00 0.00 527.96 89.99 52.41 36.50
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,082.67 99.87 56.27 38.53
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 404.82 0.00 0.00 0.00 0.00 313.22 103.93 56.60 37.47
Enterprise Value to Operating Cash Flow (EV/OCF)		 216.53 91.77 78.13 592.05 0.00 0.00 0.00 218.29 96.57 58.55 41.53
Enterprise Value to Free Cash Flow (EV/FCFF)		 208.74 129.78 126.41 563.66 0.00 0.00 0.00 0.00 0.00 331.32 115.84
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -4.63 -4.66 -333.45 31.64 15.27 8.88 4.10 4.45 1.28 0.94 0.75
Long-Term Debt to Equity		 -4.63 -4.66 -333.45 31.64 15.27 8.88 4.10 4.45 1.28 0.94 0.75
Financial Leverage		 7.11 5.23 6.66 24.43 20.88 29.61 -14.35 -13.37 -4.28 -3.10 -2.63
Leverage Ratio		 -19.47 -15.08 -18.03 -60.25 -52.55 -77.41 34.65 34.02 10.75 7.85 6.31
Compound Leverage Factor		 -19.60 -16.54 -28.39 -61.51 -54.80 -101.83 54.21 27.66 6.48 6.58 4.84
Debt to Total Capital		 127.58% 127.33% 100.30% 96.94% 93.85% 89.88% 80.38% 81.64% 56.08% 48.42% 42.75%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 127.58% 127.33% 100.30% 96.94% 93.85% 89.88% 80.38% 81.64% 56.08% 48.42% 42.75%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -27.58% -27.33% -0.30% 3.06% 6.15% 10.12% 19.62% 18.36% 43.92% 51.58% 57.25%
Debt to EBITDA		 -2.89 -4.93 19.64 -4.94 -3.41 -3.75 -3.54 9.46 1.79 1.26 0.97
Net Debt to EBITDA		 4.15 6.75 -31.72 8.81 5.78 6.12 6.55 -15.79 -3.42 -2.53 -2.24
Long-Term Debt to EBITDA		 -2.89 -4.93 19.64 -4.94 -3.41 -3.75 -3.54 9.46 1.79 1.26 0.97
Debt to NOPAT		 -5.17 -8.30 14.23 -7.77 -8.28 -12.70 -8.14 5.61 2.07 1.36 1.00
Net Debt to NOPAT		 7.43 11.37 -22.98 13.86 14.04 20.74 15.06 -9.37 -3.95 -2.73 -2.29
Long-Term Debt to NOPAT		 -5.17 -8.30 14.23 -7.77 -8.28 -12.70 -8.14 5.61 2.07 1.36 1.00
Altman Z-Score		 1.99 1.31 3.33 3.70 2.94 3.83 4.78 7.15 7.21 6.40 5.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.08 3.17 3.01 2.75 2.78 3.04 2.80 2.54 2.76 3.13 3.05
Quick Ratio		 2.86 2.86 2.78 2.57 2.61 2.84 2.63 2.37 2.51 2.89 2.79
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 224 226 192 137 -91 -46 -17 96 -385 -364 -470
Operating Cash Flow to CapEx		 -194.62% -628.34% 1,548.49% 1,042.63% -1,040.93% -1,319.00% 1,075.56% 2,677.56% 702.19% 322.92% 942.11%
Free Cash Flow to Firm to Interest Expense		 7.15 6.42 5.78 3.99 -2.33 -1.18 -0.41 1.14 -2.90 -5.25 -5.72
Operating Cash Flow to Interest Expense		 -0.95 -2.31 3.73 1.27 -2.43 -3.06 3.82 3.89 1.23 1.02 3.98
Operating Cash Flow Less CapEx to Interest Expense		 -1.44 -2.68 3.49 1.15 -2.66 -3.29 3.46 3.75 1.06 0.70 3.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.50 0.56 0.63 0.52 0.56 0.58 0.57 0.71 0.81 0.92 0.95
Accounts Receivable Turnover		 6.46 7.41 8.84 6.17 6.13 6.35 5.62 4.87 6.28 6.59 6.49
Inventory Turnover		 2.85 2.85 3.31 3.57 3.86 4.12 5.17 6.83 8.46 10.99 11.58
Fixed Asset Turnover		 3.48 3.83 4.49 4.06 4.37 4.59 4.84 6.36 7.31 8.43 9.12
Accounts Payable Turnover		 4.04 4.58 4.56 4.24 4.49 3.74 4.57 5.49 6.68 7.34 9.29
Days Sales Outstanding (DSO)		 56.47 49.27 41.27 59.18 59.51 57.47 64.98 74.97 58.13 55.43 56.22
Days Inventory Outstanding (DIO)		 128.23 128.21 110.43 102.30 94.62 88.67 70.55 53.44 43.15 33.22 31.52
Days Payable Outstanding (DPO)		 90.32 79.69 80.06 86.15 81.23 97.55 79.93 66.51 54.64 49.74 39.29
Cash Conversion Cycle (CCC)		 94.39 97.79 71.63 75.33 72.90 48.59 55.60 61.90 46.64 38.90 48.45
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1,689 -1,618 -1,654 -1,793 -1,671 -1,560 -1,649 -1,502 -1,134 -947 -965
Invested Capital Turnover		 -1.19 -1.34 -1.49 -1.23 -1.34 -1.48 -1.49 -1.95 -2.65 -3.42 -3.68
Increase / (Decrease) in Invested Capital		 -306 -257 -158 -191 17 58 5.35 291 538 613 684
Enterprise Value (EV)		 22,553 17,356 29,086 33,483 28,612 33,281 40,619 58,036 50,612 41,859 37,872
Market Capitalization		 24,021 18,755 30,738 35,308 30,350 34,956 42,518 59,772 52,535 43,881 40,191
Book Value per Share		 ($1.76) ($1.74) ($0.02) $0.25 $0.52 $0.89 $1.92 $1.78 $5.97 $8.11 $10.14
Tangible Book Value per Share		 ($1.76) ($1.74) ($0.02) $0.25 $0.52 $0.89 $1.92 $1.78 $5.97 $8.11 $10.14
Total Capital		 800 802 1,020 1,056 1,092 1,141 1,277 1,274 1,797 2,085 2,365
Total Debt		 1,021 1,022 1,023 1,024 1,025 1,026 1,027 1,040 1,008 1,009 1,011
Total Long-Term Debt		 1,021 1,022 1,023 1,024 1,025 1,026 1,027 1,040 1,008 1,009 1,011
Net Debt		 -1,468 -1,399 -1,651 -1,825 -1,738 -1,675 -1,900 -1,736 -1,923 -2,022 -2,319
Capital Expenditures (CapEx)		 15 13 8.02 4.19 9.09 8.97 14 12 23 22 35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -424 -324 -507 -645 -585 -440 -515 -327 -324 -139 -200
Debt-free Net Working Capital (DFNWC)		 2,015 2,047 2,118 2,135 2,109 2,193 2,343 2,397 2,584 2,870 3,108
Net Working Capital (NWC)		 2,015 2,047 2,118 2,135 2,109 2,193 2,343 2,397 2,584 2,870 3,108
Net Nonoperating Expense (NNE)		 56 36 51 58 10 70 55 136 -34 44 50
Net Nonoperating Obligations (NNO)		 -1,468 -1,399 -1,651 -1,825 -1,738 -1,675 -1,900 -1,736 -1,923 -2,022 -2,319
Total Depreciation and Amortization (D&A)		 13 25 25 27 14 14 14 14 14 14 14
Debt-free, Cash-free Net Working Capital to Revenue		 -23.22% -16.19% -21.63% -30.81% -26.04% -18.72% -20.91% -10.20% -8.73% -3.25% -4.17%
Debt-free Net Working Capital to Revenue		 110.21% 102.17% 90.33% 101.91% 93.81% 93.38% 95.16% 74.68% 69.58% 66.94% 64.69%
Net Working Capital to Revenue		 110.21% 102.17% 90.33% 101.91% 93.81% 93.38% 95.16% 74.68% 69.58% 66.94% 64.69%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.09) ($0.52) ($0.13) ($0.87) ($0.66) ($0.44) ($0.51) $1.91 $1.43 $1.55 $1.23
Adjusted Weighted Average Basic Shares Outstanding		 124.91M 126.14M 126.73M 128.59M 127.65M 129.68M 130.63M 131.45M 131.00M 132.89M 133.61M
Adjusted Diluted Earnings per Share		 ($1.06) ($0.52) ($0.13) ($0.87) ($0.66) ($0.44) ($0.51) $1.84 $1.44 $1.51 $1.21
Adjusted Weighted Average Diluted Shares Outstanding		 124.91M 126.14M 126.73M 128.59M 127.65M 129.68M 130.63M 137.35M 134.68M 138.23M 138.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 125.95M 126.49M 128.38M 128.98M 129.46M 130.39M 131.08M 132.11M 132.62M 133.51M 133.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -81 -30 34 -54 -74 13 -11 258 92 250 214
Normalized NOPAT Margin		 -18.53% -6.15% 5.16% -10.75% -12.41% 2.13% -1.47% 20.62% 8.40% 21.39% 16.59%
Pre Tax Income Margin		 -31.31% -12.86% -1.69% -21.69% -32.70% -7.00% -4.57% 19.13% 14.69% 18.99% 13.77%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.36 -1.64 -0.21 -3.10 -4.77 -0.82 -0.56 3.52 2.01 3.82 2.82
NOPAT to Interest Expense		 -2.60 -0.86 1.02 -1.57 -1.89 0.33 -0.28 4.63 1.15 3.60 2.61
EBIT Less CapEx to Interest Expense		 -4.85 -2.01 -0.45 -3.22 -5.01 -1.05 -0.92 3.37 1.84 3.50 2.40
NOPAT Less CapEx to Interest Expense		 -3.09 -1.23 0.78 -1.69 -2.12 0.10 -0.64 4.48 0.97 3.29 2.19
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Alnylam Pharmaceuticals is showing strong revenue growth and consistent profitability in early 2026, but its balance sheet and cash flow still reflect a business that is spending heavily to support that growth.

In Q1 2026, revenue rose to $1.17 billion from $1.10 billion in Q4 2025 and $594 million in Q1 2025. Net income came in at $206.0 million, up from $186.4 million a year earlier, while diluted EPS improved to $1.51 from $1.44. The company also generated $70.5 million of operating cash flow in the quarter.

That said, Alnylam’s cash flow remains lumpy because of large working-capital swings and ongoing investment activity. Operating cash flow dropped sharply from $163.6 million in Q4 2025 and $325.1 million in Q3 2025, and the company continued to invest in property and investments while maintaining a sizable cash and investment cushion.

  • Revenue growth remains strong: Q1 2026 revenue of $1.17 billion was up from $1.10 billion in Q4 2025 and nearly double Q1 2025 levels.
  • Profitability improved year over year: Net income rose to $206.0 million in Q1 2026 from $186.4 million in Q4 2025 and $168.9 million in Q2 2025.
  • Gross margin looks healthy: Q1 2026 gross profit was $956.1 million on $1.17 billion of revenue, showing strong top-line economics.
  • Earnings per share improved: Diluted EPS was $1.51 in Q1 2026 versus $1.44 in Q4 2025 and a loss in earlier 2025 quarters.
  • Balance sheet liquidity is solid: Cash and equivalents plus short-term investments totaled about $3.01 billion at March 31, 2026.
  • Cash position increased sequentially: Cash and equivalents rose to $1.71 billion from $1.49 billion in Q3 2025.
  • Operating cash flow turned positive but remains volatile: Q1 2026 operating cash flow was $70.5 million, below the $163.6 million in Q4 2025 but far better than the negative quarters seen in 2024 and early 2025.
  • Capital spending is manageable: Purchases of property, plant and equipment were $21.8 million in Q1 2026, a relatively modest use of cash.
  • Share count remains elevated: Diluted weighted average shares were 138.2 million in Q1 2026, suggesting ongoing dilution risk from equity issuance.
  • Working capital absorbed a lot of cash: Changes in operating assets and liabilities reduced operating cash flow by $285.4 million in Q1 2026.
  • Interest burden is meaningful: Cash interest paid was $64.2 million in Q1 2026, which is still a significant drag on cash generation.
  • Debt remains on the balance sheet: Long-term debt stood at about $1.01 billion at quarter-end.

Bottom line: Alnylam looks like a company that is transitioning into a stronger earnings profile, with impressive revenue growth and a much better profit picture than a year ago. The main caution for investors is that cash generation can swing sharply from quarter to quarter, and the company still carries debt and continues to lean on capital markets to some extent. For now, the trend in the income statement is clearly improving, while the cash flow story remains less predictable.

08/16/26 12:49 AM ETAI Generated. May Contain Errors.

Alnylam Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Alnylam Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Alnylam Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $313.75 million in 2025, falling from -$290.07 million in 2015. The previous period was -$278.16 million in 2024. Check out Alnylam Pharmaceuticals' forecast to explore projected trends and price targets.

Alnylam Pharmaceuticals' total operating income in 2025 was $501.58 million, based on the following breakdown:
  • Total Gross Profit: $3.03 billion
  • Total Operating Expenses: $2.53 billion

Over the last 10 years, Alnylam Pharmaceuticals' total revenue changed from $41.10 million in 2015 to $3.71 billion in 2025, a change of 8,937.0%.

Alnylam Pharmaceuticals' total liabilities were at $4.18 billion at the end of 2025, a 0.1% increase from 2024, and a 3,329.6% increase since 2015.

In the past 10 years, Alnylam Pharmaceuticals' cash and equivalents has ranged from $180.90 million in 2015 to $1.66 billion in 2025, and is currently $1.66 billion as of their latest financial filing in 2025.

Over the last 10 years, Alnylam Pharmaceuticals' book value per share changed from 14.93 in 2015 to 5.97 in 2025, a change of -60.0%.


Related Companies

Financial statements for NASDAQ:ALNY last updated on 7/30/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The Greatest Wealth Transfer Since the Internet Boom Just Started
Wall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...
Altimetry | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
The dollar just broke
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel